

David W Dodick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6934703/publications.pdf>

Version: 2024-02-01

257
papers

21,451
citations

7069

78
h-index

10708

138
g-index

276
all docs

276
docs citations

276
times ranked

8434
citing authors

#	ARTICLE	IF	CITATIONS
1	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. <i>Annals of Neurology</i> , 1999, 46, 878-886.	2.8	832
2	Narrative Review: Reversible Cerebral Vasoconstriction Syndromes. <i>Annals of Internal Medicine</i> , 2007, 146, 34.	2.0	807
3	OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 921-936.	1.8	779
4	Fremanezumab for the Preventive Treatment of Chronic Migraine. <i>New England Journal of Medicine</i> , 2017, 377, 2113-2122.	13.9	573
5	Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. <i>Lancet, The</i> , 2008, 372, 2115-2123.	6.3	486
6	Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Headache</i> , 2007, 47, 170-180.	1.8	446
7	ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. <i>Cephalalgia</i> , 2018, 38, 1026-1037.	1.8	416
8	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. <i>Lancet Neurology, The</i> , 2010, 9, 373-380.	4.9	413
9	Evaluation of Galcanezumab for the Prevention of Episodic Migraine. <i>JAMA Neurology</i> , 2018, 75, 1080.	4.5	413
10	Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1999.	3.8	379
11	Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. <i>Cephalalgia</i> , 2011, 31, 271-285.	1.8	358
12	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. <i>Lancet Neurology, The</i> , 2014, 13, 1100-1107.	4.9	333
13	Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. <i>Lancet Neurology, The</i> , 2014, 13, 885-892.	4.9	332
14	Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT _{1B/1D} Agonists) in the Acute Treatment of Migraine. <i>Headache</i> , 2004, 44, 414-425.	1.8	327
15	Migraine. <i>Lancet, The</i> , 2018, 391, 1315-1330.	6.3	327
16	Adherence to oral migraine-preventive medications among patients with chronic migraine. <i>Cephalalgia</i> , 2015, 35, 478-488.	1.8	314
17	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2016, 15, 382-390.	4.9	312
18	A Phase-by-Phase Review of Migraine Pathophysiology. <i>Headache</i> , 2018, 58, 4-16.	1.8	272

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. <i>Cephalalgia</i> , 2012, 32, 1165-1179.	1.8	266
20	Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. <i>Cephalalgia</i> , 2017, 37, 470-485.	1.8	256
21	Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. <i>Cephalalgia</i> , 2011, 31, 712-722.	1.8	251
22	Thunderclap headache. <i>Lancet Neurology</i> , The, 2006, 5, 621-631.	4.9	250
23	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. <i>Cephalalgia</i> , 2018, 38, 815-832.	1.8	245
24	BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. <i>Cephalalgia</i> , 2014, 34, 114-125.	1.8	241
25	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. <i>Lancet Neurology</i> , The, 2015, 14, 1081-1090.	4.9	236
26	Ubrogepant for the Treatment of Migraine. <i>New England Journal of Medicine</i> , 2019, 381, 2230-2241.	13.9	230
27	Clinical, Anatomical, and Physiologic Relationship Between Sleep and Headache. <i>Headache</i> , 2003, 43, 282-292.	1.8	220
28	A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. <i>Cephalalgia</i> , 2016, 36, 887-898.	1.8	218
29	Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double-blind, Placebo-controlled Study. <i>Headache</i> , 2005, 45, 315-324.	1.8	215
30	Functional MRI of migraine. <i>Lancet Neurology</i> , The, 2015, 14, 81-91.	4.9	210
31	Central Sensitization Theory of Migraine: Clinical Implications. <i>Headache</i> , 2006, 46, S182-S191.	1.8	206
32	Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program. <i>Headache</i> , 2010, 50, 1406-1418.	1.8	191
33	Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study. <i>Cephalalgia</i> , 2015, 35, 344-358.	1.8	187
34	The Sinus, Allergy and Migraine Study (SAMS).. <i>Headache</i> , 2007, 47, 213-224.	1.8	186
35	Triptan-induced latent sensitization: A possible basis for medication overuse headache. <i>Annals of Neurology</i> , 2010, 67, 325-337.	2.8	181
36	Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review. <i>Headache</i> , 2013, 53, 437-446.	1.8	179

#	ARTICLE	IF	CITATIONS
37	Chronic Daily Headache. <i>New England Journal of Medicine</i> , 2006, 354, 158-165.	13.9	178
38	Trial of Galcanezumab in Prevention of Episodic Cluster Headache. <i>New England Journal of Medicine</i> , 2019, 381, 132-141.	13.9	178
39	OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. <i>Journal of the Neurological Sciences</i> , 2013, 331, 48-56.	0.3	168
40	Tau Positron-Emission Tomography in Former National Football League Players. <i>New England Journal of Medicine</i> , 2019, 380, 1716-1725.	13.9	165
41	Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. <i>Headache</i> , 2016, 56, 821-834.	1.8	160
42	United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. <i>Journal of Pain</i> , 2016, 17, 1068-1080.	0.7	156
43	Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. <i>Cephalalgia</i> , 2019, 39, 687-710.	1.8	154
44	Migraine. <i>Nature Reviews Disease Primers</i> , 2022, 8, 2.	18.1	154
45	Pathophysiology, prevention, and treatment of medication overuse headache. <i>Lancet Neurology</i> , The, 2019, 18, 891-902.	4.9	151
46	National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. <i>Neurology</i> , 2021, 96, 848-863.	1.5	149
47	Treatment of medication-overuse headache: A systematic review. <i>Cephalalgia</i> , 2016, 36, 371-386.	1.8	148
48	Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention. <i>JAMA Neurology</i> , 2018, 75, 187.	4.5	147
49	Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. <i>Journal of Headache and Pain</i> , 2020, 21, 23.	2.5	143
50	Migraine: integrated approaches to clinical management and emerging treatments. <i>Lancet</i> , The, 2021, 397, 1505-1518.	6.3	139
51	Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 727-737.	4.9	137
52	Post-traumatic headache: epidemiology and pathophysiological insights. <i>Nature Reviews Neurology</i> , 2019, 15, 607-617.	4.9	131
53	Chronic migraine—classification, characteristics and treatment. <i>Nature Reviews Neurology</i> , 2012, 8, 162-171.	4.9	130
54	CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. <i>Cephalalgia</i> , 2019, 39, 445-458.	1.8	127

#	ARTICLE	IF	CITATIONS
55	Enhanced pain-induced activity of pain-processing regions in a case-control study of episodic migraine. <i>Cephalalgia</i> , 2014, 34, 947-958.	1.8	125
56	Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. <i>Clinical Therapeutics</i> , 2009, 31, 542-559.	1.1	124
57	Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. <i>Mayo Clinic Proceedings</i> , 2016, 91, 596-611.	1.4	123
58	Erenumab (AMG 334) in episodic migraine. <i>Neurology</i> , 2017, 89, 1237-1243.	1.5	120
59	Diagnostic Criteria for Headache Due to Spontaneous Intracranial Hypotension: A Perspective. <i>Headache</i> , 2011, 51, 1442-1444.	1.8	119
60	Triptan Nonresponder Studies: Implications for Clinical Practice. <i>Headache</i> , 2005, 45, 156-162.	1.8	116
61	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). <i>Cephalalgia</i> , 2018, 38, 1038-1048.	1.8	113
62	Topiramate Treatment of Chronic Migraine: A Randomized, Placebo-Controlled Trial of Quality of Life and Other Efficacy Measures. <i>Headache</i> , 2009, 49, 1153-1162.	1.8	112
63	Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. <i>European Journal of Neurology</i> , 2021, 28, 1716-1725.	1.7	112
64	Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study. <i>Cephalalgia</i> , 2015, 35, 959-968.	1.8	111
65	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. <i>Cephalalgia</i> , 2019, 39, 1075-1085.	1.8	107
66	Migraine and risk of stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 593-604.	0.9	107
67	Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. <i>Cephalalgia</i> , 2015, 35, 271-284.	1.8	106
68	Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences. <i>Headache</i> , 2018, 58, 1408-1426.	1.8	106
69	Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 996-1001.	0.9	105
70	Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. <i>Cephalalgia</i> , 2020, 40, 1026-1044.	1.8	105
71	Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. <i>Brain</i> , 2010, 133, 2475-2488.	3.7	103
72	Long-term safety, tolerability, and efficacy of fremanezumab in migraine. <i>Neurology</i> , 2020, 95, e2487-e2499.	1.5	97

#	ARTICLE	IF	CITATIONS
73	Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-blind, Placebo-controlled, Multicenter Trial. <i>Headache</i> , 2019, 59, 1240-1252.	1.8	96
74	Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. <i>Cephalalgia</i> , 2020, 40, 935-948.	1.8	91
75	Indomethacin-responsive headache syndromes. <i>Current Pain and Headache Reports</i> , 2004, 8, 19-26.	1.3	86
76	Migraine headache is present in the aura phase. <i>Neurology</i> , 2012, 79, 2044-2049.	1.5	85
77	TEV-48125 for the preventive treatment of chronic migraine. <i>Neurology</i> , 2016, 87, 41-48.	1.5	84
78	Pearls: Headache. <i>Seminars in Neurology</i> , 2010, 30, 074-081.	0.5	80
79	Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. <i>Cephalalgia</i> , 2019, 39, 1455-1464.	1.8	79
80	Targeting TRP Channels For Novel Migraine Therapeutics. <i>ACS Chemical Neuroscience</i> , 2014, 5, 1085-1096.	1.7	77
81	Kappa opioid receptor antagonists: A possible new class of therapeutics for migraine prevention. <i>Cephalalgia</i> , 2017, 37, 780-794.	1.8	70
82	Treatment and management of cluster headache. <i>Current Pain and Headache Reports</i> , 2001, 5, 83-91.	1.3	68
83	CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. <i>Cephalalgia</i> , 2019, 39, 1762-1775.	1.8	66
84	Vascular safety of erenumab for migraine prevention. <i>Neurology</i> , 2020, 94, e497-e510.	1.5	66
85	Spontaneous CSF leak treated with percutaneous CT-guided fibrin glue. <i>Neurology</i> , 2005, 64, 1818-1819.	1.5	65
86	Hypnic Headache: Another Indomethacin-Responsive Headache Syndrome?. <i>Headache</i> , 2000, 40, 830-835.	1.8	65
87	Botulinum Neurotoxin for the Treatment of Migraine and Other Primary Headache Disorders: From Bench to Bedside. <i>Headache</i> , 2003, 43, 25-33.	1.8	62
88	Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. <i>Cephalalgia</i> , 2014, 34, 594-604.	1.8	62
89	Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study. <i>Headache</i> , 2020, 60, 416-429.	1.8	61
90	Disability, quality of life, productivity impairment and employer costs of migraine in the workplace. <i>Journal of Headache and Pain</i> , 2021, 22, 29.	2.5	60

#	ARTICLE	IF	CITATIONS
91	Hypnic Headache: Another Indomethacin-Responsive Headache Syndrome?. <i>Headache</i> , 2000, 40, 830-835.	1.8	59
92	Atypical age-related cortical thinning in episodic migraine. <i>Cephalalgia</i> , 2014, 34, 1115-1124.	1.8	58
93	Late-life migraine accompaniments: A narrative review. <i>Cephalalgia</i> , 2015, 35, 894-911.	1.8	58
94	The Impact of Topiramate on Health-Related Quality of Life Indicators in Chronic Migraine. <i>Headache</i> , 2007, 47, 1398-1408.	1.8	57
95	Crescendo Transient Aura Attacks. <i>Stroke</i> , 2009, 40, 3725-3729.	1.0	56
96	Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. <i>Cephalalgia</i> , 2021, 41, 340-352.	1.8	56
97	Speed of Onset, Efficacy and Tolerability of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine. <i>CNS Drugs</i> , 2005, 19, 125-136.	2.7	54
98	Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. <i>Cephalalgia</i> , 2017, 37, 560-570.	1.8	54
99	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2019, 59, 1310-1323.	1.8	54
100	Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 1081-1090.	4.9	53
101	Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies. <i>Cephalalgia</i> , 2011, 31, 851-860.	1.8	51
102	Proposed new diagnostic criteria for chronic migraine. <i>Cephalalgia</i> , 2020, 40, 399-406.	1.8	50
103	Oral Almotriptan in the Treatment of Migraine: Safety and Tolerability. <i>Headache</i> , 2001, 41, 449-455.	1.8	49
104	Assessing Clinically Meaningful Treatment Effects in Controlled Trials: Chronic Migraine as an Example. <i>Journal of Pain</i> , 2015, 16, 164-175.	0.7	49
105	Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020, 40, 892-902.	1.8	47
106	Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines. <i>Headache</i> , 2017, 57, 1375-1384.	1.8	44
107	Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. <i>Headache</i> , 2021, 61, 992-1003.	1.8	44
108	Thunderclap Headache. <i>Headache</i> , 2002, 42, 309-315.	1.8	42

#	ARTICLE	IF	CITATIONS
109	Analgesic Overuse Is Not A Cause of Chronic Daily Headache. <i>Headache</i> , 2002, 42, 547-554.	1.8	42
110	DHE in the Pharmacotherapy of Migraine: Potential for a Larger Role. <i>Headache</i> , 2006, 46, S212-S220.	1.8	42
111	Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). <i>Cephalalgia</i> , 2016, 36, 203-215.	1.8	42
112	Chronic Paroxysmal Hemicrania Presenting as Otagia With a Sensation of External Acoustic Meatus Obstruction: Two Cases and a Pathophysiologic Hypothesis. <i>Headache</i> , 1998, 38, 787-791.	1.8	41
113	Headache After Resection of Acoustic Neuroma. <i>Headache</i> , 1999, 39, 89-94.	1.8	41
114	Examining the Essence of Migraine—Is it the Blood Vessel or the Brain? A Debate. <i>Headache</i> , 2008, 48, 661-667.	1.8	41
115	Spontaneous intracranial hypotension. <i>Current Pain and Headache Reports</i> , 2007, 11, 56-61.	1.3	40
116	Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. <i>Headache</i> , 2017, 57, 766-777.	1.8	40
117	Fremanezumab for preventive treatment of migraine. <i>Neurology</i> , 2018, 91, e1152-e1165.	1.5	40
118	Thunderclap Stroke: Embolic Cerebellar Infarcts Presenting as Thunderclap Headache. <i>Headache</i> , 2006, 46, 520-522.	1.8	37
119	Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies. <i>Headache</i> , 2020, 60, 348-359.	1.8	37
120	Epidemiology, Risk Factors, and Treatment of Chronic Migraine: A Focus on Topiramate. <i>Headache</i> , 2008, 48, 1087-1095.	1.8	35
121	Three-dimensional measurement of essential tremor. <i>Movement Disorders</i> , 1999, 14, 288-294.	2.2	34
122	Hemicrania Continua: An Indomethacin-Responsive Case With an Underlying Malignant Etiology. <i>Headache</i> , 2002, 42, 527-529.	1.8	34
123	Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. <i>Headache</i> , 2020, 60, 2220-2231.	1.8	34
124	Headache as a symptom of ominous disease. <i>Postgraduate Medicine</i> , 1997, 101, 46-64.	0.9	33
125	Best Practices for Patients With Chronic Migraine. <i>Mayo Clinic Proceedings</i> , 2015, 90, 408-414.	1.4	33
126	Comprehensive management of patients presenting to the otolaryngologist for Sinus pressure, pain, or headache. <i>Laryngoscope</i> , 2015, 125, 303-310.	1.1	33

#	ARTICLE	IF	CITATIONS
127	Systematic review of outcomes and endpoints in acute migraine clinical trials. <i>Headache</i> , 2021, 61, 263-275.	1.8	33
128	Operational Diagnostic Criteria for Chronic Migraine: Expert Opinion. <i>Headache</i> , 2014, 54, 1258-1266.	1.8	32
129	Evaluation and Management of Asymptomatic Carotid Artery Stenosis. <i>Mayo Clinic Proceedings</i> , 2004, 79, 937-944.	1.4	31
130	Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine. <i>CNS Drugs</i> , 2007, 21, 73-82.	2.7	31
131	Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine. <i>Cephalalgia</i> , 2017, 37, 1350-1372.	1.8	31
132	Pathophysiology and Management of Transformed Migraine and Medication Overuse Headache. <i>Seminars in Neurology</i> , 2006, 26, 232-241.	0.5	30
133	Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database. <i>Headache</i> , 2007, 48, 070629211050002-???	1.8	30
134	Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database. <i>Cephalalgia</i> , 2016, 36, 862-874.	1.8	30
135	The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. <i>Headache</i> , 2020, 60, 337-347.	1.8	30
136	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 136.	3.0	30
137	Painful ophthalmoplegia: Overview with a focus on tolosa-hunt syndrome. <i>Current Pain and Headache Reports</i> , 2004, 8, 321-329.	1.3	29
138	Chronic Daily Headache. <i>Neurology</i> , 2011, 76, S37-43.	1.5	29
139	Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. <i>Cephalalgia</i> , 2019, 39, 945-956.	1.8	29
140	Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. <i>Headache</i> , 2021, 61, 351-362.	1.8	29
141	Extratrigeminal Episodic Paroxysmal Hemicrania. Further Clinical Evidence of Functionally Relevant Brain Stem Connections. <i>Headache</i> , 1998, 38, 794-798.	1.8	28
142	Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomes. <i>PLoS ONE</i> , 2018, 13, e0198741.	1.1	28
143	Systematic review of outcomes and endpoints in preventive migraine clinical trials. <i>Headache</i> , 2021, 61, 253-262.	1.8	28
144	Patient-Centered Treatment of Chronic Migraine With Medication Overuse. <i>Neurology</i> , 2022, 98, .	1.5	28

#	ARTICLE	IF	CITATIONS
145	Thunderclap headache: An approach to a neurologic emergency. <i>Current Neurology and Neuroscience Reports</i> , 2007, 7, 101-109.	2.0	27
146	Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 939-944.	0.9	27
147	Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. <i>Headache</i> , 2021, 61, 1411-1420.	1.8	27
148	Predictors of allodynia in persons with migraine: Results from the Migraine in America Symptoms and Treatment (MAST) study. <i>Cephalalgia</i> , 2019, 39, 873-882.	1.8	26
149	Real-world efficacy, tolerability, and safety of ubrogepant. <i>Headache</i> , 2021, 61, 620-627.	1.8	25
150	Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study. <i>Headache</i> , 2021, 61, 734-739.	1.8	25
151	Efficacy of (S)-lacosamide in preclinical models of cephalic pain. <i>Pain Reports</i> , 2016, 1, e565.	1.4	24
152	Vancouver Declaration on Global Headache Patient Advocacy 2018. <i>Cephalalgia</i> , 2018, 38, 1899-1909.	1.8	24
153	Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data. <i>Journal of Primary Care and Community Health</i> , 2020, 11, 215013272096368.	1.0	24
154	Effect of Migraine on Pregnancy Planning: Insights From the American Registry for Migraine Research. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2079-2089.	1.4	23
155	Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. <i>Clinics in Dermatology</i> , 2004, 22, 76-81.	0.8	22
156	Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists. <i>Current Treatment Options in Neurology</i> , 2019, 21, 17.	0.7	22
157	Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. <i>Cephalalgia</i> , 2019, 39, 52-60.	1.8	22
158	Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR). <i>Headache</i> , 2020, 60, 1910-1919.	1.8	22
159	Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of Tolerability and Effectiveness in Migraine Patients using Preventive Treatment (ATTAIN) study. <i>Headache</i> , 2021, 61, 438-454.	1.8	22
160	Risk of Development of Medication Overuse Headache With Nonsteroidal Anti-inflammatory Drug Therapy for Migraine. <i>Neurologist</i> , 2011, 17, 297-299.	0.4	21
161	King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletes. <i>Neurology: Clinical Practice</i> , 2017, 7, 464-473.	0.8	21
162	World Brain Day 2019: migraine, the painful truth. <i>Lancet Neurology</i> , The, 2019, 18, 914.	4.9	21

#	ARTICLE	IF	CITATIONS
163	A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. <i>Cephalalgia</i> , 2021, 41, 305-317.	1.8	21
164	The Face of Chronic Migraine: Epidemiology, Demographics, and Treatment Strategies. <i>Neurologic Clinics</i> , 2009, 27, 467-479.	0.8	20
165	Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome. <i>Headache</i> , 2021, 61, 766-776.	1.8	20
166	Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. <i>Brain</i> , 2022, 145, 2894-2909.	3.7	20
167	Almotriptan Increases Sustained Pain-Free Outcomes in Acute Migraine: Results From Three Controlled Clinical Trials. <i>Headache</i> , 2002, 42, 21-27.	1.8	19
168	Revised 2004 International Classification of Headache Disorders: New Headache Types. <i>Canadian Journal of Neurological Sciences</i> , 2004, 31, 304-314.	0.3	19
169	Procedural Headache Medicine in Neurology Residency Training: A Survey of <sc>US</sc> Program Directors. <i>Headache</i> , 2016, 56, 79-85.	1.8	19
170	Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research. <i>Headache</i> , 2020, 60, 506-514.	1.8	19
171	Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. <i>Cephalalgia</i> , 2021, 41, 1135-1151.	1.8	19
172	Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura. <i>JAMA Neurology</i> , 2022, 79, 159.	4.5	19
173	The Effect of In-School Saccadic Training on Reading Fluency and Comprehension in First and Second Grade Students. <i>Journal of Child Neurology</i> , 2017, 32, 104-111.	0.7	17
174	Characterization and preclinical evaluation of a protease activated receptor 2 (PAR2) monoclonal antibody as a preventive therapy for migraine. <i>Cephalalgia</i> , 2020, 40, 1535-1550.	1.8	17
175	CGRP monoclonal antibody prevents the loss of diffuse noxious inhibitory controls (DNIC) in a mouse model of post-traumatic headache. <i>Cephalalgia</i> , 2021, 41, 749-759.	1.8	17
176	Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project. <i>Current Pain and Headache Reports</i> , 2004, 8, 435-442.	1.3	15
177	Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. <i>Cephalalgia</i> , 2011, 31, 296-300.	1.8	15
178	Milestone-compatible neurology resident assessments. <i>Neurology</i> , 2015, 84, 2279-2283.	1.5	15
179	Headache research in 2015: progress in migraine treatment. <i>Lancet Neurology</i> , The, 2016, 15, 4-5.	4.9	15
180	Cannabinoids induce latent sensitization in a preclinical model of medication overuse headache. <i>Cephalalgia</i> , 2020, 40, 68-78.	1.8	15

#	ARTICLE	IF	CITATIONS
181	Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. <i>Headache</i> , 2021, 61, 422-429.	1.8	15
182	<i>Headache and Other Craniofacial Pain.</i> , 2008, , 2011-2062.		15
183	Efficacy, Tolerability, and Safety of DFNâ€15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Study. <i>Headache</i> , 2020, 60, 58-70.	1.8	14
184	A review of the clinical efficacy and tolerability of almotriptan in acute migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1157-1163.	0.9	13
185	Impact of abuse on migraineâ€related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research. <i>Headache</i> , 2021, 61, 740-754.	1.8	13
186	Advances in migraine management: implications for managed care organizations. <i>Managed Care</i> , 2004, 13, 45-51.	0.3	12
187	Development and validation of a novel patientâ€reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary. <i>Headache</i> , 2022, 62, 89-105.	1.8	12
188	Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficultâ€toâ€Treat Migraine Headaches. <i>Headache</i> , 2019, 59, 509-517.	1.8	11
189	The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving â€50%, â€75%, and 100% Response. <i>Headache</i> , 2020, 60, 2026-2040.	1.8	11
190	Subconcussive brain vital signs changes predict head-impact exposure in ice hockey players. <i>Brain Communications</i> , 2021, 3, fcab019.	1.5	11
191	Familial Hemiplegic Migraine: Permanent Attackâ€Related Neurologic Deficits. <i>Headache</i> , 2007, 47, 1210-1212.	1.8	10
192	Occipital Nerve Stimulation for Migraine: Update from Recent Multicenter Trials. <i>Progress in Neurological Surgery</i> , 2016, 29, 117-126.	1.3	10
193	A Cross-Study Analysis for Reproducible Sub-classification of Traumatic Brain Injury. <i>Frontiers in Neurology</i> , 2018, 9, 606.	1.1	10
194	The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. <i>Headache</i> , 2018, 58, 973-985.	1.8	10
195	Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2021, 61, 103-116.	1.8	10
196	Treatment of cluster headache. <i>Annals of Indian Academy of Neurology</i> , 2018, 21, 9.	0.2	10
197	Migraine with aura associates with a higher artificial intelligence: <scp>ECG</scp> atrial fibrillation prediction model output compared to migraine without aura in both women and men. <i>Headache</i> , 2022, 62, 939-951.	1.8	10
198	Thunderclap headache. <i>Current Pain and Headache Reports</i> , 2002, 6, 226-232.	1.3	9

#	ARTICLE	IF	CITATIONS
199	A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, e1.63-e1.	0.9	9
200	Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review. <i>Headache</i> , 2022, 62, 453-472.	1.8	9
201	Reflections and Speculations on Refractory Migraine: Why Do Some Patients Fail to Improve With Currently Available Therapies?. <i>Headache</i> , 2008, 48, 828-837.	1.8	8
202	Taking the headache out of migraine. <i>Neurology: Clinical Practice</i> , 2015, 5, 317-325.	0.8	8
203	Mild traumatic brain injury affects the features of migraine. <i>Journal of Headache and Pain</i> , 2021, 22, 80.	2.5	8
204	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. <i>Brain</i> , 2023, 146, 1186-1199.	3.7	8
205	Headache: challenging conventional wisdom. <i>Lancet Neurology, The</i> , 2009, 8, 12-14.	4.9	7
206	Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial. <i>Cephalalgia</i> , 2021, 41, 1053-1064.	1.8	7
207	Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 105-111.	2.0	7
208	A Not So Uncommon Cause of Thunderclap Headache. <i>Headache</i> , 2002, 42, 555-555.	1.8	6
209	Suboccipital steroid injections for cluster headache. <i>Lancet Neurology, The</i> , 2011, 10, 867-869.	4.9	6
210	Ice Hockey Summit II: Zero Tolerance for Head Hits and Fighting. <i>PM and R</i> , 2015, 7, 283-295.	0.9	6
211	Disability and Economic Loss Caused by Headache among Information Technology Workers in Korea.		

#	ARTICLE	IF	CITATIONS
217	Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition. Cephalalgia, 2022, 42, 1099-1115.	1.8	5
218	The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research. Headache, 2022, 62, 566-576.	1.8	5
219	Rates of Response to Atogepant for Migraine Prophylaxis Among Adults. JAMA Network Open, 2022, 5, e2215499.	2.8	5
220	Carotid endarterectomy. Postgraduate Medicine, 2000, 107, 97-109.	0.9	3
221	55-Year-Old Man With Thunderclap Headache. Mayo Clinic Proceedings, 2010, 85, e44-e47.	1.4	3
222	Site of effect of LY2951742 for migraine prophylaxis—Authors' reply. Lancet Neurology, The, 2015, 14, 32-33.	4.9	3
223	Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. Pain and Therapy, 2020, 9, 683-694.	1.5	3
224	The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. Pain and Therapy, 2020, 9, 695-707.	1.5	3
225	The need for continued care after sponsor closure—Authors' reply. Lancet Neurology, The, 2020, 19, 205-206.	4.9	3
226	Acute Treatment of Migraine with Celecoxib Oral Solution: Results of a Randomized, Placebo-Controlled Clinical Trial. Journal of Pain Research, 2021, Volume 14, 549-560.	0.8	3
227	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. Cephalalgia, 2021, 41, 033310242110289.	1.8	3
228	Preclinical assessment of onabotulinumtoxinA for the treatment of mild traumatic brain injury-related acute and persistent post-traumatic headache. Cephalalgia, 2022, , 033310242210998.	1.8	3
229	10 Ten Most Commonly Asked Questions About Headaches Associated With Spontaneous Cerebrospinal Fluid Leaks With One Bonus Question!. Neurologist, 2002, 8, 371-374.	0.4	2
230	Current and emerging treatment options for migraine and other primary headache disorders. Expert Review of Neurotherapeutics, 2003, 3, 845-872.	1.4	2
231	Botulinum Toxin Type A (Botox) for Prophylactic Treatment of Chronic Daily Headache: A Response. Headache, 2006, 46, 529-530.	1.8	2
232	Headache attributed to disorders of homeostasis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 627-642.	1.0	2
233	Migraine and the vascular system: Much has been learned but still a long way to go. Cephalalgia, 2015, 35, 83-84.	1.8	2
234	The Non-Inferiority Margins in Migraine Research (NIMM) Survey. Headache, 2017, 57, 729-736.	1.8	2

#	ARTICLE	IF	CITATIONS
235	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. , 1999, 46, 878.		2
236	Chronic Daily Headache. , 2006, , 70-77.		2
237	A review of the clinical efficacy and tolerability of almotriptan in acute migraine. , 0, .		2
238	Patient-focused migraine management: establishing needs. Drugs of Today, 2003, 39 Suppl D, 3-9.	0.7	2
239	Stroke Telemedicine for Arizona Rural Residents, the Legacy Telestroke Study. Telemedicine Reports, 2022, 3, 67-78.	0.5	2
240	Sumatriptan versus eletriptan: which is best?. Lancet Neurology, The, 2002, 1, 474.	4.9	1
241	Anatomical landmarks for localizing the otic ganglion: A possible new treatment target for headache disorders. Cephalalgia Reports, 2019, 2, 251581631985076.	0.2	1
242	The Medical History: The Key to Correct Headache Diagnosis. , 2011, , 181-196.		1
243	Botulinum toxin type A for the prophylactic treatment of primary headache disorders. , 2007, , 229-242.		0
244	CASE 1: The Well-Intentioned Triptan Prescriber. Headache, 2008, 48, 862-864.	1.8	0
245	Primary stabbing headache. , 0, , 116-119.		0
246	Journal report from the Editor. Cephalalgia, 2011, 31, 3-3.	1.8	0
247	New research article preparation guidelines. Cephalalgia, 2013, 33, 995-997.	1.8	0
248	In Response to. Clinical Journal of Sport Medicine, 2014, 24, 521.	0.9	0
249	Letter from the Editor-in-Chief. Cephalalgia, 2015, 35, 1239-1239.	1.8	0
250	Response to Letter to the Editor. Cephalalgia, 2015, 35, 1034-1035.	1.8	0
251	Board Walk “September 2017. Cephalalgia, 2017, 37, 1009-1010.	1.8	0
252	Approach to History Taking and the Physical Examination. , 0, , 15-25.		0

#	ARTICLE	IF	CITATIONS
253	Medication Overuse Headache in the Emergency Department. , 0, , 99-109.		0
254	Epidemiology and acute care of migraine headache. Managed Care Interface, 2004, 17 Suppl D, 6-10; discussion 11-3.	0.2	0
255	Preventing migraine pharmacologically. Managed Care Interface, 2004, 17 Suppl D, 14-7, 22; discussion 23-30.	0.2	0
256	Treatment of chronic migraine with medication overuse: A perspective. Headache, 2022, 62, 642-644.	1.8	0
257	207â€¦ OnabotA for CM: benefits beyond headache-day reduction. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A73.1-A73.	0.9	0